These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9366339)

  • 1. More data on prostatic cancer--how valuable are they?
    Fitzpatrick JM
    J Urol; 1997 Dec; 158(6):2180-1. PubMed ID: 9366339
    [No Abstract]   [Full Text] [Related]  

  • 2. Gleason score from needle biopsy of the prostate predicts that from radical prostatectomy in most cases.
    Yu DS
    J Chin Med Assoc; 2005 Apr; 68(4):162. PubMed ID: 15850064
    [No Abstract]   [Full Text] [Related]  

  • 3. [Value of free PSA/total PSA ratio in therapeutic decisions in the case of a single positive biopsy of the prostate].
    Huyghe E; Soulie M; Tollon C; Escourrou G; Pontonnier F; Plante P
    Prog Urol; 1999 Apr; 9(2):281-7. PubMed ID: 10370952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PSA volume quotient: an additional parameter in diagnosis of locally confined prostate cancer].
    Gottfried HW; Kleinschmidt K; Flohr P; Miller K; Hautmann R
    Urologe A; 1993 Nov; 32(6):455-9. PubMed ID: 7506850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic possibilities of prostate biopsy].
    Pushkar' DIu; Govorov AV
    Urologiia; 2002; (6):46-51. PubMed ID: 12577581
    [No Abstract]   [Full Text] [Related]  

  • 6. The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.
    Dolejsova O; Kucera R; Fuchsova R; Topolcan O; Svobodova H; Hes O; Eret V; Pecen L; Hora M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818787377. PubMed ID: 30021484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of the COVID-19 pandemic on early detection of prostate cancer in Australia.
    Ip CCK; Kealey J; Davis ID; Sengupta S
    BJU Int; 2021 Dec; 128 Suppl 3(Suppl 3):6-8. PubMed ID: 34750958
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer.
    Yu J; Kwon YS; Kim S; Han CS; Farber N; Kim J; Byun SS; Kim WJ; Jeon SS; Kim IY
    J Urol; 2016 May; 195(5):1464-1470. PubMed ID: 26608903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new marker for prostate cancer is evaluated].
    Fath R; Ikinger U
    Aktuelle Urol; 2004 Sep; 35(5):365-6. PubMed ID: 15383999
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Kim et al.: detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/ml (Urology 2010;76:919-922).
    Shenoy SP; Marla PK; Adappa KK
    Urology; 2011 Apr; 77(4):1013-4; author reply 1014. PubMed ID: 21477737
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
    Scaletscky R; Koch MO; Eckstein CW; Bicknell SL; Gray GF; Smith JA
    J Urol; 1994 Jul; 152(1):129-31. PubMed ID: 7515448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number.
    Ploussard G; Azancot V; Nicolaiew N; Xylinas E; Salomon L; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    BJU Int; 2010 Nov; 106(9):1293-7. PubMed ID: 20456338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.
    Vickers A; Carlsson S; Laudone V; Lilja H
    Eur Urol; 2014 Aug; 66(2):188-90. PubMed ID: 24411991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy diagnosis of prostatic cancer--current areas of concern.
    Feneley MR; Parkinson MC
    J Clin Pathol; 1997 Apr; 50(4):265-6. PubMed ID: 9215135
    [No Abstract]   [Full Text] [Related]  

  • 15. Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
    Taverna G; Colombo P; Seveso M; Giusti G; Piccinelli A; Benetti A; Graziotti P
    Arch Ital Urol Androl; 2006 Jun; 78(2):57-60. PubMed ID: 16929604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
    Shinohara K; Wolf JS; Narayan P; Carroll PR
    J Urol; 1994 Jul; 152(1):120-3. PubMed ID: 7515447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer with low PSA levels.
    Glaser AI
    N Engl J Med; 2004 Oct; 351(17):1802-3. PubMed ID: 15499670
    [No Abstract]   [Full Text] [Related]  

  • 19. pT0 prostate cancer after radical prostatectomy.
    Gross JL; Masterson TA; Cheng L; Johnstone PA
    J Surg Oncol; 2010 Sep; 102(4):331-3. PubMed ID: 20589707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging.
    Linder BJ; Kawashima A; Woodrum DA; Tollefson MK; Karnes J; Davis BJ; Rangel LJ; King BF; Mynderse LA
    Can J Urol; 2014 Jun; 21(3):7283-9. PubMed ID: 24978358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.